MBI Group announced on Friday that it has completed a project to construct and renovate patient care spaces at The Mount Sinai Hospital's Guggenheim Pavilion, located at 1190 Fifth Avenue on Manhattan's Upper East Side.
The company added that it was selected under a competitive bid process .
Under the four-month project, MBI was responsible for the renovation of patient spaces in the haematology, oncology and bone marrow transplant unit. The renovations of patient rooms, nursing stations, restrooms and corridors included interior demolition, millwork, drywall, ceiling work, tiling, terrazzo, flooring, painting, toilet installation, wall protection, plumbing and HVAC, as well as electrical work.
Founded in 1852, The Mount Sinai Hospital is one of the oldest and largest teaching hospitals in the US. The integrated health care system provides exceptional medical care to local and global communities. It is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties.
Established in 1987, MBI Group is a full-service construction firm providing interior fit-outs and core and shell construction for corporate, educational, healthcare, hospitality, institutional, mixed-use and retail facilities.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA